Author: admin

(Bloomberg) — Japan’s exports rose at a faster pace as businesses increased orders ahead of the rollout of higher tariffs in the US. Most Read from Bloomberg Exports measured by value gained 11.4% in February from a year earlier, the Ministry of Finance reported Wednesday. Exports slightly missed the median estimate of a 12.6% increase. Imports fell 0.7%, compared with the median estimate of a 0.8% gain. Japan’s trade balance switched back into the black, with a surplus of ¥584.5 billion ($3.9 billion). Trade helped Japan’s economy grow in the last quarter of 2024 as net exports rose, and shipments…

US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…

(Bloomberg) — Japan’s exports rose at a faster pace as businesses increased orders ahead of the rollout of higher tariffs in the US. Most Read from Bloomberg Exports measured by value gained 11.4% in February from a year earlier, the Ministry of Finance reported Wednesday. Exports slightly missed the median estimate of a 12.6% increase. Imports fell 0.7%, compared with the median estimate of a 0.8% gain. Japan’s trade balance switched back into the black, with a surplus of ¥584.5 billion ($3.9 billion). Trade helped Japan’s economy grow in the last quarter of 2024 as net exports rose, and shipments…

(Bloomberg) — Japan’s exports rose at a faster pace as businesses increased orders ahead of the rollout of higher tariffs in the US. Most Read from Bloomberg Exports measured by value gained 11.4% in February from a year earlier, the Ministry of Finance reported Wednesday. Exports slightly missed the median estimate of a 12.6% increase. Imports fell 0.7%, compared with the median estimate of a 0.8% gain. Japan’s trade balance switched back into the black, with a surplus of ¥584.5 billion ($3.9 billion). Trade helped Japan’s economy grow in the last quarter of 2024 as net exports rose, and shipments…

US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…

(Bloomberg) — Japan’s exports rose at a faster pace as businesses increased orders ahead of the rollout of higher tariffs in the US. Most Read from Bloomberg Exports measured by value gained 11.4% in February from a year earlier, the Ministry of Finance reported Wednesday. Exports slightly missed the median estimate of a 12.6% increase. Imports fell 0.7%, compared with the median estimate of a 0.8% gain. Japan’s trade balance switched back into the black, with a surplus of ¥584.5 billion ($3.9 billion). Trade helped Japan’s economy grow in the last quarter of 2024 as net exports rose, and shipments…

US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…

(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…

US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…

(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…